ENDOMETRIAL CANCER METASTATIC

This adverse event was reported 162 times

These drugs are most commonly taken by patients reporting ENDOMETRIAL CANCER METASTATIC:

# Drug Count
0 CONJUGATED ESTROGENS 16
1 ESTROGENS, CONJUGATED 16
2 PACLITAXEL 16
3 CARBOPLATIN 15
4 MEDROXYPROGESTERONE ACETATE 10
5 DENOSUMAB 9
6 BEVACIZUMAB 8
7 EVEROLIMUS 8
8 IBUPROFEN 8
9 METHOTREXATE 8
See all common drugs associated with ENDOMETRIAL CANCER METASTATIC

ENDOMETRIAL CANCER METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BENZOCAINE AND DEXTROMETHORPHAN HYDROBROMIDE 1 0.0040
1 BENZOCAINE AND MENTHOL 1 0.0038
2 BACTERIOSTATIC WATER 1 0.0024
3 CETYLPYRIDINIUM CHLORIDE 1 0.0015
4 DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE 1 0.0012
5 PROCHLORPERAZINE EDISYLATE 1 0.0008
6 ERDAFITINIB 1 0.0008
7 METRELEPTIN 1 0.0008
8 MEGESTROL ACETATE 2 0.0005
9 DEFEROXAMINE MESYLATE 1 0.0005
See all drugs enriched for association with ENDOMETRIAL CANCER METASTATIC

ENDOMETRIAL CANCER METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 1 0.0015
1 Leptin Analog [EPC] 1 0.0008
2 alpha-Hydroxy Acid [EPC] 1 0.0005
3 alpha-Glucosidase Inhibitor [EPC] 1 0.0002
4 Programmed Death Receptor-1 Blocking Antibody [EPC] 13 0.0001
5 Progesterone [EPC] 3 0.0001
6 Nuclear Export Inhibitor [EPC] 1 0.0001
7 Microtubule Inhibitor [EPC] 16 0.0001
8 Estrogen [EPC] 18 0.0001
9 Anti-anginal [EPC] 1 0.0001
See all drug classes enriched for association with ENDOMETRIAL CANCER METASTATIC